Lenalidomide treatment has been approved by Food and Drug Administration for patients with transfusion-dependent anemia due to low and int-1 myelodysplastic syndrome associated with 5q deletion with or without additional cytogenetic abnormalities. [1] [2] [3] Erythroid response to lenalidomide is associated with meaningful increases in hemoglobin (Hb), red blood cell transfusion independence, cytogenetic response and probably overall survival. [1] [2] [3] [4] Lenalidomide is effective regardless of previous epoetin or thalidomide treatment. Whereas erythroid responses occurred in 83% of patients with 5q deletion, responses were also achieved in patients with a normal karyotype (57%) and with other cytogenetic abnormalities (12%). [1] [2] [3] Wei et al. 5 previously reported that lenalidomide acts to relieve suppression of the epoetin-receptor signal in myelodysplastic syndrome erythroid precursors, suggesting that the erythropoietic activity of lenalidomide might be improved by combined treatment with erythropoiesis-stimulating agent (ESA). Lenalidomide has also a direct cytotoxicity against 5qÀ positive cells. 5 Recently, in transfusion-dependent myelodysplastic syndrome patients, resistant to lenalidomide alone, the combination lenalidomide þ ESA induced 25% of erythroid response (preliminary results). 6 To evaluate the potential benefit of the combination of lenalidomide and ESA, we tried the association in three del5q myelodysplastic syndrome patients, who were resistant or partially responding to lenalidomide alone.
A 67-year-old woman presented with anemia. In 2004, her Hb was at 9 g/dl, mean corpuscular volume (MCV) 111 fl, platelets were at 360 Â 10 9 /l and leukocytes 5.15 Â 10 9 /l, 2270 polymorphonuclear neutrophils (PNN). She had a medullar aspiration, with 3% of blasts and dysmyelopoiesis with hypolobulated megakaryocytes; a diagnosis of refractory cytopenia with multilineage dysplasia was made. Karyotype was abnormal with del 5 (q13q31) in all mitosis, leading to the diagnosis of 5qÀ syndrome. serum erythropoietin (sEPO) level was 42.5 mUI/ml. Darbepoetin was introduced on February 2004 at 300 mg/week. Hb level rose from 10.8 to 15 g/dl after 12 weeks. Sustained response according to IWG 2006 was obtained for 5 years and a half. A medullar aspiration was done and still showed dysmyelopoiesis and monolobulated megakaryocytes with no increase of blasts. Then during summer 2009, she presented with Hb 10.5 g/dl, MCV 121 fl, leukocytes 7.5 Â 10 9 /l and 6.69 Â 10 9 /l PNN, and 366 Â 10 9 /l platelets. Lenalidomide 10 mg/day for 21 days was introduced on July 2009 according to the recommendations of the Groupe Francophone des Myélodysplasies (http://www.gfmgroup.org/ recommandation/recommandation_20081114170733.pdf). After 3 months of lenalidomide alone, Hb level was stable at around 10.3 g/dl, platelets decreasing from 262 Â 10 9 /l to 84 Â 10 9 /l, corresponding to a failure of response. Moreover, the patient did not tolerate the dosage of lenalidomide 10 mg/day because of tiredness. Lenalidomide was decreased to 5 mg/day for 21 days and darbepoetin 300 mg/week was added to lenalidomide. Hb rose dramatically from 10 to 14 g/dl with a MCV at 110 mm 3 after 1 month (Figure 1a) . The medullar aspiration after 3 months of treatment showed complete cytogenetic remission with absence of del 5(q13q31) in 12 mitosis and in 200 cells analysed using FISH. She is still currently a responder with a follow-up of 12 months.
A 68-year-old patient presented with bicytopenia since 2002 with Hb 10.6 g/dl, MCV 88 fl, leukopenia 2.5 Â 10 9 /l, platelets 230 Â 10 9 /l without any deficiency in vitamin B12 and in folic acid. During the following years, the patient's Hb decreased to 8.4 g/dl. On 2005, medullar aspiration was poor and bone marrow biopsy showed a desert and adipous bone marrow, rare haematopoietic islands with a moderate interstitial fibrosis. Karyotype showed 46, XY, del (5q) (q13-q33) (3)/46, XY (20). Progenitor culture on methylcellulose showed a decreased number of Colony-Forming Units-Erythroid (CFU-E) at day 7 and of Burst-Forming Units-Erythroid (BFU-E) at day 14. No argument for a paroxystic hemoglobinuria clone was found. A diagnosis of myelodysplastic syndrome with aplastic form and del5q was done. He was transfused with red blood cell for 2 years every 15 days. Then, he was injected with darbepoietin 300 mg/week for 12 weeks without efficacy on the rhythm of red blood cell transfusions. He obtained lenalidomide in a compassionate use on March 2007 at 10 mg/day for 21 days every 28 days for 2 months and then at 5 mg/day during 3 months because of digestive side effects. He was stopped being transfused after 1 month of treatment but his Hb was stable at around 10 g/dl. On August 2007, epoetin beta 30 000 UI/week was added to lenalidomide 5 mg/day and his Hb rose to 13.3 g/dl on December 2007 (Figure 1b) . Platelets count was stable at around 148 Â 10 9 /l and leukocytes 6.46 Â 10 9 /l. He was still a responder for 2 years. But on October 2009, his Hb decreased to 9.3 g/dl, and the platelets dropped to 51 Â 10 9 /l, and peripheral blasts were present at 8%. A medullar aspiration showed a transformation to RAEB-2 with 16% of blasts. Karyotype was still normal. 5-azacytidine treatment was introduced on December 2009.
A woman of 72 years, with a previous history of breast cancer treated by surgery and radiotherapy presented in 1996 with a blood count revealing a normocytic anemia and all medullar investigations concluded to a 5qÀ syndrome. She was transfused regularly every 15 days since 1999. She received epoetin beta þ granulocyte colony-stimulating factor in 2001, without efficacy, than thalidomide 200 mg/day in 2003 with digestive side effects. In October 2005, she had Hb 9.1 g/dl, MCV 82 fl, reticulocytes 12 Â 10 9 /l, platelets 102 Â 10 9 /l and PNN 2.8 Â 10 9 /l before introduction of lenalidomide, with 6% of blasts on the medullogram, erythroblastopenia (1% of erythroid lineage), and monolobulated megakaryocytes evoking 5qÀ syndrome. Karyotype revealed 46, XX, del 5(q14q34) in 20 mitosis. She received lenalidomide 10 mg/day in compassionate use and improved her Hb level to 12 g/dl. After 6 months, lenalidomide was decreased to 5 mg/day and the Hb level was stabilized to 12 g/dl, the karyotype showed only 10% of mitosis with del5q. The medullar aspiration at 6 months of treatment revealed a hyperplasia of the erythroid lineage at 47% with a persistence of blasts at 6%. She responded for 1 year and after that Hb level decreased to 8.5 g/dl and she required regular red blood cell transfusions. The medullar aspiration was not modified. Karyotype showed a del5qÀ in 3 mitosis out of 20 and a del20qÀ (3/20). sEPO level was 418 UI/l. Then she received lenalidomide at 5 mg/day þ darbepoetin 150 mg/week since June 2007, and she maintained an Hb level at 12 g/dl even 14.5 g/dl for 1 more year (Figure 1c) . Then she transformed to acute myeloid leukemia, 10 years after her diagnosis.
In these three patients, lenalidomide alone was not efficient (case 1 and 2) or the third case relapsed after 1 year of efficacy. The adjunction of ESA restored an erythroid response in association with lenalidomide. The median time to response to lenalidomide þ ESA was short at around 4 weeks (range 2-8 weeks), and the increase of Hb was dramatic. In the third case, it is interesting to note the cytogenetic response to lenalidomide alone correlating with a moderate erythroid response. The adjunction of ESA permitted a complete erythroid response.
Lenalidomide could therefore have two different actions: one on the disappearance of the 5qÀ clone in cases 1 and 3 5 and the other one on the stimulation of the erythroid production in combination with ESA. 7, 8 These cases suggest the benefits of the association of a low dose of lenalidomide and an ESA, after intolerance or loss of response to lenalidomide alone, as if lenalidomide sensitized the erythroid clones to ESA again. List et al. 6 have previously pinpointed the interest of the association of these two agents in vitro with pharmacological data.
Biological studies could be performed to confirm these effects. Further studies randomizing lenalidomide alone, against lenalidomide þ ESA are ongoing in the USA (NCT00843882) and in Europe.
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The authors declare no conflict of interest. The majority of chronic phase-chronic myeloid leukaemia (CP-CML) patients respond well to the first generation tyrosine kinase inhibitor, imatinib. However, 25-30% of patients fare less well, exhibiting suboptimal response or treatment failure. We have demonstrated that the functional activity of the OCT-1 protein (termed OCT-1 activity) assayed in patient mononuclear cells before the start of imatinib therapy is a key determinant of both short-and long-term response to imatinib in previously untreated CP-CML. 1,2 A greater proportion of patients with high OCT-1 activity (4 median value defined in the Tidel study of 7.2 ng per 200 000 cells) 1 achieve major molecular response (MMR) when compared with patients with low OCT-1 activity (89 vs 55%; P ¼ 0.007). Furthermore, a low OCT-1 activity is significantly associated with lower overall survival to 5 years (87 vs 96%; P ¼ 0.028) and event-free survival (48 vs 74%; P ¼ 0.03), as well as a higher Abl kinase domain mutation rate (21 vs 4%; P ¼ 0.047). The interpatient variability observed in OCT-1 activity remains unexplained. It has been suggested that the level of OCT-1 mRNA is predictive of response to imatinib, 3 however this has yet to be demonstrated in a large cohort of previously untreated patients. It is possible that non-synonymous, single-nucleotide polymorphisms (SNPs) that result in an altered OCT-1 protein may well impact on the functional activity of this protein and, therefore, on response to therapy.
In a recent publication Bazeos et al. 4 explored SNPs as possible predictive factors for imatinib response. In this study they investigated the frequency of seven previously reported SNPs in a cohort of 132 CML patients treated with imatinib in chronic phase. They also explored, the impact of four of these SNP's (R61C, P341L, G401S and rs6222342) on the achievement of MMR, and found that the G401S (rs34130495) SNP was significantly associated with a higher rate of MMR (P ¼ 0.0155).
It is interesting that this polymorphism has been previously described by Shu and Kerb 5, 6 and has been demonstrated to result in a reduced function protein with respect to transport of the model OCT-1 substrates MPP and tetraethylammonium (TEA). Thus, its association with an increased rate of MMR is surprising. It is also evident that the frequency of this SNP is low (frequency in the tested population 0.045, frequency in European Americans Shu 0.011), 5 thus its presence would not account for many cases of MMR observed in CP-CML patients treated with imatinib.
We have screened 136 newly diagnosed CP-CML patients presenting to our Centre for the presence of the commonly reported non-synonymous SNPs of OCT-1; 5 Reduced-function SNPs(R61C, G401S, C88R and P341L), loss of function SNPs (G220V and G465R) and the SNPs reported not to alter function (M408V and M420del) using direct sequencing. As demonstrated in Table 1 the most common SNP's in our patient cohort were the M408V and the M420del with observed frequencies of 0.38 and 0.29, respectively. The G220V SNP was not detectable in any patient tested and the C88R, P341L and G465R were each only detectable in one patient. These frequencies are in keeping with previous reports in European/American populations. 5 The M408V and the M420del SNPs are thought to be associated with normal transport of the model substrates TEA and MPP. 5 However, the M420del has more recently been associated with decreased transport of the diabetes drug metformin. 7 This exemplifies the considerable substrate variability in the impact of SNPs, and validates screening SNPs, with a frequency 40.10 for possible therapeutic effect.
Where SNPs were detected at sufficient frequency (n ¼ 4) we then assessed the achievement of MMR by 24 months in patients with and without SNPs. Log rank and w 2 analysis revealed that, in this cohort of patients, the presence of either R61C, G401S or M408V (homozygous or heterozygous) and M420del (homozygous or heterozygous) had no significant effect on the achievement of MMR by 24 months (P ¼ 0.949, 0.411, 0.112,
